Nasdaq Welcomes Zealand Pharma (Nasdaq:ZEAL) to The Nasdaq Stock Market
August 10 2017 - 12:57PM
Zealand Pharma (Nasdaq:ZEAL), a biotechnology company focused on
the discovery, design and development of innovative peptide-based
medicines, visited the Nasdaq MarketSite in Times Square today in
celebration of its initial public offering (IPO) on The Nasdaq
Stock Market this week.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/5499f1d5-5aea-4c2a-a4d4-37be20473f46
http://www.globenewswire.com/NewsRoom/AttachmentNg/79d11059-5065-4457-b85c-69c3425152dd
Zealand Pharma has a portfolio that includes two approved
products for the treatment of type 2 diabetes: Soliqua® 100/33 and
Adlyxin®/Lyxumia®. Both products were launched in the U.S. earlier
this year by its partner Sanofi. In addition, their pipeline
includes gastrointestinal and metabolic product candidates,
addressing specialty diseases with significant unmet medical
needs.
“We are very excited and believe it is the perfect time for
Zealand Pharma to list in the United States. In June 2017, we
achieved positive clinical results for two late stage product
candidates, thus the listing and the capital raised in conjunction
with the listing should enable us to progress development of these
products,” said Britt Meelby Jensen, President and CEO of Zealand
Pharma A/S.
“Zealand Pharma has a track record of successfully inventing and
developing their novel peptide-based product candidates. Their
history of innovation makes them a perfect fit into the Nasdaq
family of disruptors, and we are proud to stand by them on their
journey as a public company,” said Nelson Griggs, Executive Vice
President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational
and educational purposes only, and nothing contained herein should
be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Information about the
company is provided by the company or comes from the company’s
public filings and is not independently verified by Nasdaq.
Neither Nasdaq nor any of its affiliates makes any recommendation
to buy or sell any security or any representation about the
financial condition of any company. Statements regarding
Nasdaq-listed companies are not guarantees of future performance.
Actual results may differ materially from those expressed or
implied. Past performance is not indicative of future results.
Investors should undertake their own due diligence and carefully
evaluate companies before investing. ADVICE FROM A SECURITIES
PROFESSIONAL IS STRONGLY ADVISED.
About NasdaqNasdaq (Nasdaq:NDAQ) is a
leading global provider of trading, clearing, exchange technology,
listing, information and public company services. Through its
diverse portfolio of solutions, Nasdaq enables customers to plan,
optimize and execute their business vision with confidence, using
proven technologies that provide transparency and insight for
navigating today's global capital markets. As the creator of the
world's first electronic stock market, its technology powers more
than 90 marketplaces in 50 countries, and 1 in 10 of the world's
securities transactions. Nasdaq is home to approximately
3,900 total listings with a market value of approximately $12
trillion. To learn more, visit: http://business.nasdaq.com
- NDAQG -
Media Relations Contacts:
Stephanie Lowenthal
(646) 441-5073
Stephanie.Lowenthal@nasdaq.com
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024